Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT00426218 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Juvenile Rheumatoid

Interventions

DRUG: ACZ885

Sponsor

Novartis